OPXA’s Q2/10 net loss was $1.82 M or ($0.12) per share. Opexa reported no revenues in Q2/10. R&D expenses were $785,103. The increase in expenses was primarily related to an increase in personnel, the initiation of key experiments which was partially offset by a decrease in stock compensation expense. G&A expenses were $595,424. The increase in expense is due to an increase in professional service fees and again was partially offset by a decrease in stock compensation expense. Cash and cash equivalents were $5.9 M as of 6/30/10.
- Implementation of process improvements and optimization of manufacturing process to support late stage clinical trials and regulatory requirements;
- Preparation for clinical studies and positioning for future FDA interactions;
- Enlisting the support of worldwide thought leaders in MS, neurology, and immunology for newly reconstituted SAB.